The US biopharma major expands its footprint in India, strengthening Hyderabad’s position as a hub for technology, life sciences, and pharmaceutical research.
According to the latest reports, the US biopharma company Amgen is set to establish a science and innovation hub in Hyderabad to expand its footprint in India. This adds to the city’s growing portfolio of global life sciences and pharmaceutical operations. The facility is planned for Genome Valley, one of India’s prominent clusters for biotechnology, pharmaceutical research and related industries.
The move is part of Amgen’s broader effort to expand its global research and development capabilities. The company already operates research labs in several locations worldwide, and the Hyderabad centre is expected to contribute to its wider scientific and innovation network.
Amgen’s operations in Hyderabad will focus on science, tech, and innovation.
Amgen’s Hyderabad operations are expected to bring together capabilities across technology, artificial intelligence, data science, and life sciences. The company has previously said its India operations would support the development of digital capabilities across its global organisation and help advance its medicines pipeline. The company’s decision to build its presence in Hyderabad reflects the increasing overlap between biotechnology and advanced digital technologies. AI, data analytics and computational tools are becoming increasingly relevant to pharmaceutical research, from analysing biological data to supporting drug development programmes.
Amgen’s India operations were initially planned to accommodate up to 3,000 employees. The company subsequently announced a $200 million investment commitment for its Hyderabad technology and innovation centre during 2025, with additional investment expected in later years.
Hyderabad strengthens its life sciences position.
The expansion adds to Hyderabad’s growing role in India’s life sciences ecosystem. Genome Valley has attracted pharmaceutical, biotechnology and research companies, while the city’s wider technology sector provides access to specialists in artificial intelligence, data science and other digital disciplines.
The development also reflects a wider trend among multinational healthcare and pharmaceutical companies, which are expanding their technology and research capabilities in India. Hyderabad’s combination of specialised talent, an established pharmaceutical ecosystem and a strong technology base has helped attract such investments.
Amgen’s new science and innovation centre therefore adds another layer to Hyderabad’s evolving identity as a location where biotechnology, healthcare research and digital technology increasingly intersect.
